Stem Cells http://www.peprotech.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sondak, V. K.
Right arrow Articles by Kern, D. H.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sondak, V. K.
Right arrow Articles by Kern, D. H.

International Journal of Cell Cloning, Vol 6, 378-391, Copyright © 1988 by AlphaMed Press

ORIGINAL ARTICLES

In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay

VK Sondak, EL Korn and DH Kern
Division of Surgical Oncology, University of Michigan Medical School, Ann Arbor.

A total of 199 solid human tumors were tested with a rapid thymidine incorporation assay for sensitivity to one of several clinically used multi-drug combinations and to each agent in the combination separately. Melanomas, lung and breast cancers accounted for the majority of specimens. In 120 specimens, at least one single agent exhibited in vitro activity (80% or greater inhibition of thymidine incorporation), and in 116 of these (96.7%) the drug combination was active in vitro. In the 79 specimens where no single agent was active in vitro, the combination was also inactive in 62 (78.5%). Overall, there was concordance of in vitro activity of the most active single agent and the combination of agents in 89.5% of specimens tested. A lack of significant in vitro synergy was noted in all of the drug combinations and tumor types tested. Of note is the fact that in 141 of the 199 tests (70.9%) either no drug (n = 79) or only 1 drug (n = 62) demonstrated in vitro activity. We conclude that the rapid thymidine incorporation assay can be used to test for in vitro sensitivity to drug combinations, and that sensitivity to a drug combination can be inferred if a tumor is sensitive to any component drug of the combination.


This article has been cited by other articles:


Home page
 JCOHome page
P. Cortazar and B. E. Johnson
Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer
J. Clin. Oncol., May 1, 1999; 17(5): 1625 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
K. T. Robbins, N. M. Varki, A. M. Storniolo, H. Hoffman, and R. M. Hoffman
Drug Response of Head and Neck Tumors in Native-State Histoculture
Arch Otolaryngol Head Neck Surg, January 1, 1991; 117(1): 83 - 86.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 1988 by AlphaMed Press.